Brought to you by 
GSK buys ID Biomedical for $1.4bn
04 Oct 2005
Executive Summary
GlaxoSmithKline PLC has agreed to acquire Canadian vaccine developer ID Biomedical for $1.4bn ($Cdn1.6bn) in cash. GSK is paying $29.45 ($Cdn35) per share, a 17% premium to the market average. Included in the price is GSK's assumption of the company's $77mm debt.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
GSK buys ID Biomedical for $1.4bn
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice